Real‐World Healthcare Resource Utilisation in Patients With Higher‐Risk Myelodysplastic Syndrome During Azacitidine Treatment: A Population‐Based Cohort Study

Real‐World Healthcare Resource Utilisation in Patients With Higher‐Risk Myelodysplastic Syndrome During Azacitidine Treatment: A Population‐Based Cohort Study

ABSTRACT Background The hypomethylating agent azacitidine (AZA) is the most widely used first‐line treatment for patients with higher‐risk myelodysplastic syndromes (MDS) due to its survival benefits. Effective management of higher‐risk MDS requires addressing not only clinical outcomes but also the...

Full description

Saved in:
Bibliographic Details
Main Authors: Simone Juline Brommann, Linea Pilgaard, Jonas Faartoft Jensen, Anne Estrup Olesen, Daniel Tuyet Kristensen, Marianne Tang Severinsen
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:eJHaem
Subjects:
azacitidine
healthcare resource utilisation
MDS
population‐based study
Online Access:https://doi.org/10.1002/jha2.70066
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jha2.70066

Similar Items